1. One Year Results of the FDA Clinical Trial of a New Personalized Hyperopia Treatment
Stephen G Slade, MD The Laser Center of Houston Houston, Texas
Consultant for B&L, Alcon, Technolas, AMO, Revision Optics

2. Zyoptix- personalized wavefront guided platform
Technolas 217-Z excimer laser
Hartmann-Shack aberometer (Zywave)
Topography data (Orbscan II-z)
Zywave data is combined with the Orbscan data to generate the custom treatment plans.

3. Zyoptix Hyperopia FDA Trial
Six sites in U.S.
Limits of treatment range: +4.0 D sphere and D cylinder (OZ 6-7 mm surgeon decision)
Study eyes: 159 (80 patients)
Postop follow up - 1year
Without Rotational Eye Tracker
Without Advanced Nomogram for hyperopia

4. Mean MRSE
Mean Preop Sphere= 1.81 ± 1.09D (range 0-4 D) Cylinder=0.83 ± 0.67 (range 0-4)

5. Uncorrected Visual Acuity

6. Uncorrected Visual Acuity at 1 Year (n=147)

7. Change in BCVA Preop to 1 Year (n=155)

8. Refractive Error

9. Comparison to Other Systems
Achieved 20/20 or Better at 6 Months

10. Conclusion
Tecnolas 217 with Zyoptix Personalized Treatment for Hyperopia provides:
Excellent uncorrected visual acuity
Stable MRSE
Highly predictable outcomes